Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Terbuch, A; Posch, F; Partl, R; Zurl, B; Bauernhofer, T; Pichler, M; Szkandera, J; Hutterer, GC; Pummer, K; Kapp, KS; Stöger, H; Gerger, A; Stotz, M.
Risk stratification for febrile neutropenia in patients with testicular germ cell tumors.
Cancer Med. 2018; 7(2):508-514 Doi: 10.1002/cam4.1317 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Gerger Armin
Terbuch Angelika
Co-Autor*innen der Med Uni Graz
Bauernhofer Thomas
Hutterer Georg
Kapp Karin S.
Partl Richard
Pichler Martin
Posch Florian
Pummer Karl
Stöger Herbert
Stotz Michael
Szkandera Joanna
Zurl Brigitte

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

The aim of this study was to detect risk factors for febrile neutropenia (FN) in patients with testicular germ cell tumors (TGCT). In this retrospective cohort study at the Medical University of Graz, we included 413 consecutive TGCT patients who received adjuvant or curative treatment with cisplatin-based chemotherapy. FN occurred in 70 (16.9%) of 413 patients. In univariable logistic regression, higher age (odds ratio (OR) per 5 years = 1.17, 95% CI: 1.02-1.35, P = 0.022), reduced performance status (PS) (OR = 2.73, 1.47-5.06, P = 0.001), seminomatous histology (OR = 2.19, 1.26-3.78, P = 0.005), poor IGCCCG risk class (OR = 4.20, 1.71-10.33, P = 0.002), and prior radiotherapy (pRTX) (OR = 8.98, 2.09-38.61, P = 0.003) were associated with a higher risk of FN. In multivariable analysis adjusting for age and risk classification, only poor PS (OR = 2.06, 1.05-4.03, P = 0.035), seminomatous histology (OR = 2.08, 1.01-4.26, P = 0.047), and pRTX (OR = 7.31, 1.61-33.17, P = 0.010) prevailed. In the subgroup of seminoma patients (n = 104), only pRTX predicted for FN risk (OR = 5.60, 1.24-25.34, P = 0.025). Five of eight seminoma patients with pRTX developed FN (63%), as compared to 22 FN cases (23%) in the 96 seminoma patients without pRTX (P = 0.027). The eight seminoma patients who received pRTX had significantly lower pre-chemo white blood counts (4.7 vs. 6.5 G/L), neutrophil counts (3.2 vs. 4.3 G/L), and platelet counts (185 vs. 272 G/L) than patients without pRTX (all P < 0.0001). TGCT patients with a reduced performance status or who had been previously treated with radiotherapy have an increased risk for neutropenic fever during chemotherapy. © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemoradiotherapy - adverse effects
Cisplatin - administration & dosage
Cisplatin - adverse effects
Febrile Neutropenia - diagnosis
Febrile Neutropenia - etiology
Humans -
Logistic Models -
Male -
Multivariate Analysis -
Neoplasms, Germ Cell and Embryonal - complications
Neoplasms, Germ Cell and Embryonal - therapy
Outcome Assessment (Health Care) - methods
Outcome Assessment (Health Care) - statistics & numerical data
Retrospective Studies -
Risk Assessment - methods
Risk Assessment - statistics & numerical data
Risk Factors -
Testicular Neoplasms - complications
Testicular Neoplasms - therapy

Find related publications in this database (Keywords)
testicular cancer
febrile neutropenia
risk factors
© Med Uni Graz Impressum